Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Broncus Drug-Eluting Stent For Emphysema Slated To Debut In 2010

This article was originally published in The Gray Sheet

Executive Summary

Broncus Technologies plans a mid-2010 U.S. launch of a minimally invasive emphysema treatment system that would rely on a drug-eluting stent to bypass collapsed airways in the lung

You may also be interested in...



Emphasys’ Endobronchial Valve For Emphysema Is “Not Approvable” – Panel

Emphasys Medical's Zephyr endobronchial valve shows promise as a treatment for severe heterogeneous emphysema but lacks sufficient efficacy data to merit FDA approval, the agency's Anesthesiology and Respiratory Therapy Devices panel determined in an 11-2 vote Dec. 5

Emphasys’ Endobronchial Valve For Emphysema Is “Not Approvable” – Panel

Emphasys Medical's Zephyr endobronchial valve shows promise as a treatment for severe heterogeneous emphysema but lacks sufficient efficacy data to merit FDA approval, the agency's Anesthesiology and Respiratory Therapy Devices panel determined in an 11-2 vote Dec. 5

Financings In Brief

WorldHeart seeks to raise $30 million in stock sale: Cash-strapped maker of implantable ventricular assist devices plans to raise at least $30 million through the sale of 300 million shares of common stock by July 31 to fund continued operations, the firm says. Announced June 23, WorldHeart's planned stock sale will include investments of $10 million from venture capital firm Venrock, $9 million from private equity fund Special Situations, and other investments for which discussions are ongoing. The move is part of a broader recapitalization effort by WorldHeart that includes a $1 million bridge loan from Venrock and Special Situations, and conversion of a previous $5 million loan from Abiomed into 86 million shares of WorldHeart stock (1"The Gray Sheet" Dec. 17, 2007, p. 12). The Oakland, Calif., firm announced last month that it had only $500,000 in cash on hand and faced the possibility of bankruptcy without additional funding. In the first quarter, WorldHeart lost $11.5 million on sales of $635,996

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel